[1]Zeltins A. Construction and characterization of virus-like particles : a review. Mol Biotechnol. 2013;53:92-107.
[2]Naskalska A., Pyrć K. Virus Like Particles as Immunogens and Universal Nanocarriers. Polish Journal of Microbiology. 2015;64:3-13.
[3]Galla M., Will E., Kraunus J., Chen L., Baum C. Retroviral pseudotransduction for targeted cell manipulation. Mol Cell. 2004;16:309-315.
[4]Prel A., Caval V., Gayon R., Ravassard P. Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles. Mol Ther Methods Clin Dev. 2015;2:15039.
[6]Kaczmarczyk S.J., Sitaraman K., Young H.A., Hughes S.H., Chatterjee D.K. Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A. 2011;108:16998-17003.
[7]Voelkel C., Galla M., Maetzig T. Protein transduction from retroviral Gag precursors. Proc Natl Acad Sci U S A. 2010;107:7805-7810.
[8]Maetzig T., Baum C., Schambach A. Retroviral protein transfer: falling apart to make an impact. Curr Gene Ther. 2012;12:389-409.
[9]Lavillette D., Marin M., Ruggieri A., Mallet F., Cosset F.L., Kabat D. The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors. J Virol. 2002;76:6442-6452.
[10]Chavez A., Scheiman J., Vora S. Highly efficient Cas9-mediated transcriptional programming. Nat Methods. 2015;12:326-328.